The example
of extremely
desperate approach in drug development field:
More than 20 compounds that Pfizer Inc.
(PFE), Eli Lilly & Co. (LLY) and AstraZeneca Plc (AZN) failed to turn into
drugs will be tested by U.S.-sponsored scientists in a $20 million program to
see if they’ll work against ailments they weren’t aimed at previously.
If the compounds are effective, the time to
market will be shorter and the drugmakers, who retain ownership of the
compounds, will share profits with researchers. Traditionally, companies spend
about $2 billion and take 14 years to develop therapies, a so-called
valley-of-death commitment that’s made drugmakers move cautiously in deciding
which illness to target.
Well,
everybody knows that the whole drug development
industry experiences huge crisis but I didn’t expect that the crisis is so deep.
No comments:
Post a Comment